

Plaintiff Juan Ortiz, complaining of Defendants SYNGENTA CROP PROTECTION LLC and SYNGENTA AG, files this Complaint, and would respectfully show as follows:

1. Paraquat is a synthetic chemical compound¹ that since the mid-1960s has been developed, registered, manufactured, distributed, sold for use, and used as an active ingredient in herbicide products (“paraquat”) developed, registered, formulated, distributed, and sold for use in the United States, including the State of Washington.

PHILLIPS LAW FIRM
17410 133RD Ave NE Ste 301
Woodinville, WA 98072
p. (425) 482-1111 f.(425)-482-6653

IV. ALLEGATIONS COMMON TO ALL CAUSES OF ACTION

A. Defendants and their predecessors.

1. Syngenta Crop Protection LLC and Syngenta AG

9. In 1926, four British chemical companies merged to create the British company that then was known as Imperial Chemical Industries Ltd. and ultimately was known as Imperial Chemical Industries PLC (“ICI”).

10. In or about 1971, ICI created or acquired a wholly owned U.S. subsidiary organized under the laws of the State of Delaware, which at various times was known as Atlas Chemical Industries Inc., ICI North America Inc., ICI America Inc., and ICI United States Inc., and ultimately was known as ICI Americas Inc. (collectively “ICI Americas”).

11. In or about 1992, ICI merged its pharmaceuticals, agrochemicals, and specialty chemicals businesses, including the agrochemicals business it had operated at one time through a wholly owned British subsidiary known as Plant Protection Ltd. and later as a division within ICI, into a wholly owned British subsidiary known as ICI Bioscience Ltd.

12. In 1993, ICI demerged its pharmaceuticals, agrochemicals, and specialty chemicals businesses, from which it created the Zeneca Group, with the British company Zeneca Group PLC as its ultimate parent company.

13. As a result of ICI’s demerger and creation of the Zeneca Group, ICI Bioscience Ltd. was demerged from ICI and merged into, renamed, or continued its business under the same or similar ownership and management as Zeneca Ltd., a wholly owned British subsidiary of Zeneca Group PLC.

14. Before ICI’s demerger and creation of the Zeneca Group, ICI had a Central Toxicology Laboratory that performed and hired others to perform health and safety studies that

1 were submitted to the U.S. Department of Agriculture (“USDA”) and the U.S. Environmental
2 Protection Agency (“EPA”) to secure and maintain the registration of paraquat and other pesticides
3 for use in the United States.

4 15. As a result of ICI’s demerger and creation of the Zeneca Group, ICI’s Central
5 Toxicology Laboratory became Zeneca Ltd.’s Central Toxicology Laboratory.

6 16. After ICI’s demerger and creation of the Zeneca Group, Zeneca Ltd.’s Central
7 Toxicology Laboratory continued to perform and hire others to perform health and safety studies
8 that were submitted to EPA to secure and maintain the registration of paraquat and other pesticides
9 for use in the United States.

10 17. As a result of ICI’s demerger and creation of the Zeneca Group, ICI Americas was
11 demerged from ICI and merged into, renamed, or continued its business under the same or similar
12 ownership and management as Zeneca, Inc. (“Zeneca”), a wholly owned subsidiary of Zeneca
13 Group PLC organized under the laws of the State of Delaware.

14 18. In 1996, the Swiss pharmaceutical and chemical companies Ciba-Geigy Ltd. and
15 Sandoz AG merged to create the Novartis Group, with the Swiss company Novartis AG as the
16 ultimate parent company.

17 19. As a result of the merger that created the Novartis Group, Ciba-Geigy Corporation,
18 a wholly owned subsidiary of Ciba-Geigy Ltd. organized under the laws of the State of New York,
19 was merged into or continued its business under the same or similar ownership and management
20 as Novartis Crop Protection, Inc. (“NCPI”), a wholly owned subsidiary of Novartis AG organized
21 under the laws of the State of Delaware.

22 20. In 1999, the Swedish pharmaceutical company Astra AB merged with Zeneca
23 Group PLC to create the British company AstraZeneca PLC, of which Zeneca Ltd. and Zeneca
24

1 were wholly owned subsidiaries.

2 21. In 2000, Novartis AG and AstraZeneca PLC spun off and merged the Novartis
3 Group's crop protection and seeds businesses and AstraZeneca's agrochemicals business to create
4 the Syngenta Group, a global group of companies focused solely on agribusiness, with Defendant
5 Syngenta AG ("SAG") as the ultimate parent company.

6 22. As a result of the Novartis/AstraZeneca spinoff and merger that created the
7 Syngenta Group, Zeneca Ltd. was merged into, renamed, or continued its business under the same
8 or similar ownership and management as Syngenta Ltd., a wholly owned British subsidiary of
9 SAG.
10

11 23. As a result of the Novartis/AstraZeneca spinoff and merger that created the
12 Syngenta Group, Zeneca Ltd.'s Central Toxicology Laboratory became Syngenta Ltd.'s Central
13 Toxicology Laboratory.

14 24. Since the Novartis/AstraZeneca spinoff and merger that created the Syngenta
15 Group, Syngenta Ltd.'s Central Toxicology Laboratory has continued to perform and hire others
16 to perform health and safety studies for submission to the EPA to secure and maintain the
17 registration of paraquat and other pesticides for use in the United States.

18 25. As a result of the Novartis/AstraZeneca spinoff and merger that created the
19 Syngenta Group, NCPI and Zeneca were merged into and renamed, or continued to do their
20 business under the same or similar ownership and management, as Syngenta Crop Protection, Inc.
21 ("SCPI"), a wholly owned subsidiary of SAG organized under the laws of the State of Delaware.
22

23 26. In 2010, SCPI was converted into Defendant Syngenta Crop Protection LLC
24 ("SCPLLC"), a wholly owned subsidiary of SAG organized and existing under the laws of the
25 State of Delaware with its principal place of business in Greensboro, North Carolina.

1 27. SAG is a successor in interest to the crop-protection business of its corporate
2 predecessor Novartis AG.

3 28. SAG is a successor in interest to the crop-protection business of its corporate
4 predecessor AstraZeneca PLC.

5 29. SAG is a successor in interest to the crop-protection business of its corporate
6 predecessor Zeneca Group PLC.

7 30. SAG is a successor in interest to the crop-protection business of its corporate
8 predecessor Imperial Chemical Industries PLC, previously known as Imperial Chemical Industries
9 Ltd.

10 31. SAG is a successor in interest to the crop-protection business of its corporate
11 predecessor ICI Bioscience Ltd.

12 32. SAG is a successor in interest to the crop-protection business of its corporate
13 predecessor Plant Protection Ltd.

14 33. SCPLLC is a successor in interest to the crop-protection business of its corporate
15 predecessor SCPI.

16 34. SCPLLC is a successor in interest to the crop-protection business of its corporate
17 predecessor NCPI.

18 35. SCPLLC is a successor in interest to the crop-protection business of its corporate
19 predecessor Ciba-Geigy Corporation.

20 36. SCPLLC is a successor in interest to the crop-protection business of its corporate
21 predecessor Zeneca Inc.

22 37. SCPLLC is a successor by merger or continuation of business to its corporate
23 predecessor ICI Americas Inc., previously known as Atlas Chemical Industries Inc., ICI North
24
25

America Inc., ICI America Inc., and ICI United States Inc.

38. SCPLLC does substantial business in the State of Washington, including the following:

- a. markets, advertises, distributes, sells, and delivers paraquat and other pesticides to distributors, dealers, applicators, and farmers in the State of Washington;
- b. secures and maintains the registration of paraquat and other pesticides with the EPA and the State of Washington to enable itself and others to manufacture, distribute, sell, and use these products in the State of Washington; and
- c. performs, hires others to perform, and funds or otherwise sponsors or otherwise funds the testing of pesticides in the State of Washington.

39. SAG is a foreign corporation organized and existing under the laws of Switzerland, with its principal place of business in Basel, Switzerland.

40. SAG is a holding company that owns stock or other ownership interests, either directly or indirectly, in other Syngenta Group companies, including SCPLLC.

41. SAG is a management holding company.

42. Syngenta Crop Protection AG (“SCPAG”), a Swiss corporation with its principal place of business in Basel, Switzerland, is one of SAG’s direct, wholly owned subsidiaries.

43. SCPAG employs the global operational managers of production, distribution, and marketing for the Syngenta Group’s Crop Protection (“CP”) and Seeds Divisions.

44. The Syngenta Group’s CP and Seeds Divisions are the business units through which SAG manages its CP and Seeds product lines.

45. The Syngenta Group’s CP and Seeds Divisions are not and have never been corporations or other legal entities.

46. SCPAG directly and wholly owns Syngenta International AG (“SIAG”).

1 47. SIAG is the “nerve center” through which SAG manages the entire Syngenta
2 Group.

3 48. SIAG employs the “Heads” of the Syngenta Group’s CP and Seeds Divisions.

4 49. SIAG also employs the “Heads” and senior staff of various global functions of the
5 Syngenta Group, including Human Resources, Corporate Affairs, Global Operations, Research
6 and Development, Legal and Taxes, and Finance.

7 50. Virtually all of the Syngenta Group’s global “Heads” and their senior staff are
8 housed in the same office space in Basel, Switzerland.

9 51. SAG is the indirect parent of SCPLLC through multiple layers of corporate
10 ownership:

- 11 a. SAG directly and wholly owns Syngenta Participations AG;
- 12 b. Syngenta Participations AG directly and wholly owns Seeds JV C.V.;
- 13 c. Seeds JV C.V. directly and wholly owns Syngenta Corporation;
- 14 d. Syngenta Corporation directly and wholly owns Syngenta Seeds, LLC;
- 15 e. Syngenta Seeds, LLC directly and wholly owns SCPLLC.

16 52. Before SCPI was converted to SCPLLC, it was incorporated in Delaware, had its
17 principal place of business in North Carolina, and had its own board of directors.

18 53. SCPI’s sales accounted for more than 47% of the sales for the entire Syngenta
19 Group in 2019.

20 54. SAG has purposefully organized the Syngenta Group, including SCPLLC, in such
21 a way as to attempt to evade the authority of courts in jurisdictions in which it does substantial
22 business.

23 55. Although the formal legal structure of the Syngenta Group is designed to suggest
24
25

1 otherwise, SAG in fact exercises an unusually high degree of control over its country-specific
2 business units, including SCPLLC, through a “matrix management” system of functional
3 reporting to global “Product Heads” in charge of the Syngenta Group’s unincorporated Crop
4 Protection and Seeds Divisions, and to global “Functional Heads” in charge of human resources,
5 corporate affairs, global operations, research and development, legal and taxes, and finance.

6 56. The lines of authority and control within the Syngenta Group do not follow its
7 formal legal structure, but instead follow this global “functional” management structure.

8 57. SAG controls the actions of its far-flung subsidiaries, including SCPLLC, through
9 this global “functional” management structure.

10 58. SAG’s board of directors has established a Syngenta Executive Committee
11 (“SEC”), which is responsible for the active leadership and the operative management of the
12 Syngenta Group, including SPLLC.

13 59. The SEC consists of the CEO and various global Heads, which currently are:

- 14 a. The Chief Executive Officer;
15 b. Group General Counsel;
16 c. The President of Global Crop Protection;
17 d. The Chief Financial Officer;
18 e. The President of Global Seeds; and
19 f. The Head of Human Resources;

20 60. SIAG employs all of the members of the Executive Committee.

21 61. Global Syngenta Group corporate policies require SAG subsidiaries, including
22 SPLLC, to operate under the direction and control of the SEC and other unincorporated global
23 management teams.
24
25

1 62. SAG's board of directors meets five to six times a year.

2 63. In contrast, SCPI's board of directors rarely met, either in person or by telephone,
3 and met only a handful of times over the last decade before SCPI became SCPLLC.

4 64. Most, if not all, of the SCPI board's formal actions, including selecting and
5 removing SCPI officers, were taken by unanimous written consent pursuant to directions from the
6 SEC or other Syngenta Group global or regional managers that were delivered via e-mail to SCPI
7 board members.

8 65. Since SCPI became SCPLLC, decisions that are nominally made by the board or
9 managers of SCPLLC in fact continue to be directed by the SEC or other Syngenta Group global
10 or regional managers.

11 66. Similarly, Syngenta Seeds, Inc.'s board of directors appointed and removed SCPI
12 board members at the direction of the SEC or other Syngenta Group global or regional managers.

13 67. Since SCPI became SCPLLC, the appointment and removal of the manager(s) of
14 SCPLLC continues to be directed by the SEC or other Syngenta Group global or regional
15 managers.

16 68. The management structure of the Syngenta Group's CP Division, of which
17 SCPLLC is a part, is not defined by legal, corporate relationships, but by functional reporting
18 relationships that disregard corporate boundaries.

19 69. Atop the CP Division is the CP Leadership Team (or another body with a different
20 name but substantially the same composition and functions), which includes the President of
21 Global Crop Protection, the CP region Heads (including SCPLLC President Vern Hawkins), and
22 various global corporate function Heads.

23 70. The CP Leadership Team meets bi-monthly to develop strategy for new products,
24
25

1 markets, and operational efficiencies and to monitor performance of the Syngenta Group's
2 worldwide CP business.

3 71. Under the CP Leadership Team are regional leadership teams, including the North
4 America Regional Leadership Team (or another body with a different name but substantially the
5 same composition and functions), which oversees the Syngenta Group's U.S. and Canadian CP
6 business (and when previously known as the NAFTA Regional Leadership Team, also oversaw
7 the Syngenta Group's Mexican CP business).

8 72. The North America Regional Leadership Team is chaired by SCPLLC's president
9 and includes employees of SCPLLC and the Syngenta Group's Canadian CP company (and when
10 previously known as the NAFTA Regional Leadership Team, also included employees of the
11 Syngenta Group's Mexican CP company).

12 73. The Syngenta Group's U.S. and Canadian CP companies, including SCPLLC,
13 report to the North America Regional Leadership Team, which reports to the CP Leadership Team,
14 which reports to the SEC, which reports to SAG's board of directors.

15 74. Some members of the North America Regional Leadership Team, including some
16 SCPLLC employees, report or have in the past reported not to their nominal superiors within the
17 companies that employ them, but directly to the Syngenta Group's global Heads.

18 75. Syngenta Group Global Heads that supervise SCPLLC employees participate and
19 have in the past participated in the performance reviews of these employees and in setting their
20 compensation.

21 76. The Syngenta Group's functional reporting lines have resulted in employees of
22 companies, including SCPLLC, reporting to officers of remote parent companies, officers of
23 affiliates with no corporate relationship other than through SAG, or officers of subsidiary
24
25

1 companies.

2 77. SCPLLC performs its functions according to its role in the CP Division structure:

3 a. CP Division development projects are proposed at the global level, ranked and
4 funded at the global level after input from functional entities such as the CP Leadership
5 Team and the North America Regional Leadership Team, and given final approval by
6 the SEC;

7 b. New CP products are developed by certain Syngenta Group companies or
8 functional groups that manage and conduct research and development functions for the
9 entire CP Division;

10 c. These products are then tested by other Syngenta Group companies, including
11 SCPLLC, under the direction and supervision of the SEC, the CP Leadership Team, or
12 other Syngenta Group global managers;

13 d. Syngenta Group companies, including SCPLLC, do not contract with or
14 compensate each other for this testing;

15 e. Rather, the cost of such testing is included in the testing companies' operating
16 budgets, which are established and approved by the Syngenta Group's global product
17 development managers and the SEC;

18 f. If a product shows promise based on this testing and the potential markets for the
19 product, either global or regional leaders (depending on whether the target market is
20 global or regional), not individual Syngenta Group companies such as SCPLLC, decide
21 whether to sell the product;

22 g. Decisions to sell the product must be approved by the SEC;

23 h. The products that are sold all bear the same Syngenta trademark and logo.

24 78. SCPLLC is subject to additional oversight and control by Syngenta Group global
25 managers through a system of "reserved powers" established by SAG and applicable to all

1 Syngenta Group companies.

2 79. These “reserved powers” require Syngenta Group companies to seek approval for
3 certain decisions from higher levels within the Syngenta Group’s functional reporting structure.

4 80. For example, although SAG permits Syngenta Group companies to handle small
5 legal matters on their own, under the “reserved powers” system, SAG’s Board of Directors must
6 approve settlements of certain types of lawsuits against Syngenta Group companies, including
7 SCPLLC, if their value exceeds an amount specified in the “reserved powers.”

8 81. Similarly, the appointments of senior managers at SCPLLC must be approved by
9 higher levels than SCPLLC’s own management, board of directors, or even its direct legal owner.
10

11 82. Although SCPLLC takes the formal action necessary to appoint its own senior
12 managers, this formal action is in fact merely the rubber-stamping of decisions that have already
13 been made by the Syngenta Group’s global management.

14 83. Although SAG subsidiaries, including SCPLLC, pay lip service to legal formalities
15 that give the appearance of authority to act independently, in practice many of their acts are
16 directed or pre-approved by the Syngenta Group’s global management.

17 84. SAG and the global management of the Syngenta Group restrict the authority of
18 SCPLLC to act independently in areas including:

- 19 a. Product development;
20
21 b. Product testing (among other things, SAG and the global management of the
22 Syngenta Group require SCPLLC to use Syngenta Ltd.’s Central Toxicology
23 Laboratory to design, perform, or oversee product safety testing that SCPLLC submits
24 to the EPA in support of the registrations of paraquat and other pesticides);
25 c. Production;
d. Marketing;

- e. Sales;
- f. Human resources;
- g. Communications and public affairs;
- h. Corporate structure and ownership
- i. Asset sales and acquisitions
- j. Key appointments to boards, committees and management positions;
- k. Compensation packages;
- l. Training for high-level positions; and
- m. Finance (including day-to-day cash management) and tax.

85. Under the Syngenta Group’s functional management system, global managers initiate, and the global Head of Human Resources oversees, international assignments and compensation of managers employed by one Syngenta subsidiary to do temporary work for another Syngenta subsidiary in another country. This international assignment program aims, in part, to improve Syngenta Group-wide succession planning by developing corporate talent to make employees fit for higher positions within the global Syngenta Group of companies.

86. Under this international assignment program, at the instance of Syngenta Group global managers, SCPLLC officers and employees have been “seconded” to work at other SAG subsidiaries, and officers and employees of other Syngenta Group subsidiaries have been “seconded” to work at SCPLLC.

87. The Syngenta Group’s functional management system includes a central global finance function—known as Syngenta Group Treasury—for the entire Syngenta Group.

88. The finances of all Syngenta Group companies are governed by a global treasury policy that subordinates the financial interests of SAG’s subsidiaries, including SCPLLC, to the interests of the Syngenta Group as a whole.

1 89. Under the Syngenta Group’s global treasury policy, Syngenta Group Treasury
2 controls daily cash sweeps from subsidiaries such as SCPLLC, holds the cash on account, and
3 lends it to other subsidiaries that need liquidity.

4 90. The Syngenta Group’s global treasury policy does not allow SAG subsidiaries such
5 as SCPLLC to seek or obtain financing from non-Syngenta entities without the approval of
6 Syngenta Group Treasury.

7 91. Syngenta Group Treasury also decides whether SCPLLC will issue a dividend or
8 distribution to its direct parent company, and how much that dividend will be.

9 92. SCPLLC’s board or management approves dividends and distributions mandated
10 by Syngenta Group Treasury without any meaningful deliberation.

11 93. SAG, through its agent or alter ego, SCPLLC, does substantial business in the State
12 of Washington, in the ways previously alleged as to SCPLLC.

13
14 **B. Paraquat manufacture, distribution, and sale**

15 94. ICI, a legacy company of Syngenta, claims to have discovered the herbicidal
16 properties of paraquat in 1955.

17 95. The leading manufacturer of paraquat is Syngenta, which (as ICI) developed the
18 active ingredient in paraquat in the early 1960s.

19 96. ICI produced the first commercial paraquat formulation and registered it in England
20 in 1962.

21 97. Paraquat was marketed in 1962 under the brand name Gramoxone.

22 98. Paraquat first became commercially available for use in the United States in 1964.

23 99. In or about 1964, ICI and Chevron Chemical Company entered into agreements
24 regarding the licensing and distribution of paraquat (“the ICI-Chevron Chemical Agreements”).
25

1 100. In or about 1971, ICI Americas became a party to the ICI-Chevron Chemical
2 Agreements on the same terms as ICI.

3 101. In the ICI-Chevron Chemical Agreements, ICI and ICI Americas granted Chevron
4 Chemical a license to distribute and sell paraquat in the U.S. under the ICI-trademarked brand
5 name Gramoxone.

6 102. The ICI-Chevron Chemical Agreements were renewed or otherwise remained in
7 effect until about 1986.

8 103. SAG and its corporate predecessors have manufactured, formulated, distributed,
9 and sold paraquat for use in the United States from about 1964 through the present, and at all
10 relevant times intended or expected their paraquat products to be distributed and sold in
11 Washington, where they registered such products with the State of Washington to enable them to
12 be lawfully distributed, sold, and used in Washington, and marketed, advertised, and promoted
13 them to Washington distributors, dealers, applicators, and farmers.

14 104. SAG and its corporate predecessors have submitted health and safety and efficacy
15 studies to the USDA and the EPA to support the registration of paraquat for manufacture,
16 formulation, distribution, and sale for use in the United States from about 1964 through the present.

17 105. SCPLLC and its corporate predecessors have manufactured, formulated,
18 distributed, and sold paraquat for use in the United States from about 1971 through the present,
19 and at all relevant times intended or expected their paraquat products to be distributed and sold in
20 Washington, where they registered such products with the State of Washington to enable them to
21 be lawfully distributed, sold, and used in Washington, and marketed, advertised, and promoted
22 them to Washington distributors, dealers, applicators, and farmers.

23 106. SCPLLC and its corporate predecessors have submitted health and safety and
24
25

1 efficacy studies to the EPA to support the registration of paraquat for manufacture, formulation,
2 distribution, and sale for use in the U.S. from about 1971 through the present.

3 107. From approximately the 1989 through 2017, Plaintiff was repeatedly exposed to
4 and inhaled, ingested, or absorbed paraquat in the course of applying it as an herbicide in the
5 vicinity of Kitsap County, Washington.

6 108. As a direct result of exposure to paraquat, Plaintiff was diagnosed with PD.

7 109. No doctor or any other person ever told Plaintiff that his Parkinson's disease was
8 or could have been caused by exposure to paraquat.

9 110. Before May 2021, Plaintiff had never read or heard of any articles in newspapers,
10 scientific journals, or other publications that associated Parkinson's disease with paraquat.

11 111. Before May 2021, Plaintiff had never read or heard of any lawsuit alleging that
12 paraquat causes Parkinson's disease.

13 112. At no time when using paraquat himself was Plaintiff aware that exposure to
14 paraquat could cause any latent injury, including any neurological injury or Parkinson's disease,
15 or that any precautions were necessary to prevent any latent injury that could be caused by
16 exposure to paraquat.

17 113. The paraquat to which Plaintiff was exposed was sold and used in Washington, and
18 was manufactured, distributed, and on information and belief sold by one or more of the
19 Defendants and their corporate predecessors intending or expecting that it would be sold and used
20 in Washington.

21 114. On information and belief, Plaintiff was exposed to paraquat manufactured,
22 distributed, and sold at different times as to each Defendant and their corporate predecessors and
23 not necessarily throughout the entire period of his exposure as to any particular Defendant and
24

1 their corporate predecessors.

2 115. On information and belief, Plaintiff was exposed to paraquat that was sold and used
3 in Washington, and was manufactured, distributed, and sold by SCPLLC and its corporate
4 predecessors intending or expecting that it would be sold and used in Washington.

5 116. On information and belief, Plaintiff was exposed to paraquat that was sold and used
6 in Washington, and was manufactured, distributed, and sold by SAG and its corporate predecessors
7 intending or expecting that it would be sold and used in Washington.

8
9 **C. Paraquat use**

10 117. Since 1964, paraquat has been used in the United States to kill broadleaf weeds and
11 grasses before the planting or emergence of more than 100 field, fruit, vegetable, and plantation
12 crops, to control weeds in orchards, and to desiccate (dry) plants before harvest. At all relevant
13 times, the use of Defendants' paraquat for these purposes was intended or directed by or reasonably
14 foreseeable to, and was known to or foreseen by, Defendants.

15 118. At all relevant times, where paraquat was used, it was commonly used multiple
16 times per year on the same land, particularly when used to control weeds in orchards or on farms
17 with multiple crops planted on the same land within a single growing season or year, and such use
18 was as intended or directed or reasonably foreseeable. The use of Defendants' paraquat for these
19 purposes was intended or directed by or reasonably foreseeable to, and was known to or foreseen
20 by, Defendants.

21 119. At all relevant times, paraquat manufactured, distributed, sold, and sprayed or
22 caused to be sprayed by Defendants and Defendants' corporate predecessors was typically sold to
23 end-users in the form of liquid concentrates (and less commonly in the form of granular solids)
24 designed to be diluted with water before or after loading it into the tank of a sprayer and applied
25

1 by spraying it onto target weeds.

2 120. At all relevant times, concentrates containing paraquat manufactured, distributed,
3 sold, and sprayed or caused to be sprayed by Defendants and Defendants' corporate predecessors
4 typically were formulated with one or more "surfactants" to increase the ability of the herbicide to
5 stay in contact with the leaf, penetrate the leaf's waxy surface, and enter into plant cells, and the
6 accompanying instructions typically told end-users to add a surfactant or crop oil (which as
7 typically formulated contains a surfactant) before use.

8 121. At all relevant times, paraquat typically was applied with a knapsack sprayer, hand-
9 held sprayer, aircraft (i.e., crop duster), truck with attached pressurized tank, or tractor-drawn
10 pressurized tank, and such use was as intended or directed or was reasonably foreseeable.

11 **D. Paraquat exposure**

12 122. At all relevant times, it was reasonably foreseeable that when paraquat was used in
13 the manner intended or directed or in a reasonably foreseeable manner, users of paraquat and
14 persons nearby would be exposed to paraquat while it was being mixed and loaded into the tanks
15 of sprayers, including as a result of spills, splashes, and leaks.

16 123. At all relevant times, it was reasonably foreseeable that when paraquat was used in
17 the manner intended or directed or in a reasonably foreseeable manner, persons who sprayed
18 paraquat or were in or near areas where it was being or recently had been sprayed would be exposed
19 to paraquat, including as a result of spray drift, the movement of herbicide spray droplets from the
20 target area to an area where herbicide application was not intended, typically by wind, and as a
21 result of contact with sprayed plants.

22 124. At all relevant times, it was reasonably foreseeable that when paraquat was used in
23 the manner intended or directed or in a reasonably foreseeable manner, users of paraquat and
24 persons nearby would be exposed to paraquat, including as a result of spills, splashes, and leaks,

1 while equipment used to spray it was being emptied or cleaned or clogged spray nozzles, lines, or
2 valves were being cleared.

3 125. At all relevant times, it was reasonably foreseeable that paraquat could enter the
4 human body via absorption through or penetration of the skin, mucous membranes, and other
5 epithelial tissues, including tissues of the mouth, nose and nasal passages, trachea, and conducting
6 airways, particularly where cuts, abrasions, rashes, sores, or other tissue damage was present.

7 126. At all relevant times, it was reasonably foreseeable that paraquat could enter the
8 human body via respiration into the lungs, including the deep parts of the lungs where respiration
9 (gas exchange) occurred.

10 127. At all relevant times, it was reasonably foreseeable that paraquat could enter the
11 human body via ingestion into the digestive tract of small droplets swallowed after entering the
12 mouth, nose, or conducting airways.

13 128. At all relevant times, it was reasonably foreseeable that paraquat that entered the
14 human body via ingestion into the digestive tract could enter the enteric nervous system (the part
15 of the nervous system that governs the function of the gastrointestinal tract).

16 129. At all relevant times, it was reasonably foreseeable that paraquat that entered the
17 human body, whether via absorption, respiration, or ingestion, could enter the bloodstream.

18 130. At all relevant times, it was reasonably foreseeable that paraquat that entered the
19 bloodstream could enter the brain, whether through the blood-brain barrier or parts of the brain not
20 protected by the blood-brain barrier.

21 131. At all relevant times, it was reasonably foreseeable that paraquat that entered the
22 nose and nasal passages could enter the brain through the olfactory bulb (a part of the brain
23 involved in the sense of smell), which is not protected by the blood-brain barrier.

E. Parkinson's disease

132. PD is progressive neurodegenerative disorder of the brain that affects primarily the motor system, the part of the central nervous system that controls movement.

133. Scientists who study PD generally agree that fewer than 10% of all PD cases are caused by inherited genetic mutations alone, and that more than 90% are caused by a combination of environmental factors, genetic susceptibility, and the aging process.

1. Symptoms and treatment

134. The characteristic symptoms of PD are its “primary” motor symptoms: resting tremor (shaking movement when the muscles are relaxed), bradykinesia (slowness in voluntary movement and reflexes), rigidity (stiffness and resistance to passive movement), and postural instability (impaired balance).

135. PD's primary motor symptoms often result in “secondary” motor symptoms such as freezing of gait; shrinking handwriting; mask-like expression; slurred, monotonous, quiet voice; stooped posture; muscle spasms; impaired coordination; difficulty swallowing; and excess saliva and drooling caused by reduced swallowing movements.

136. Non-motor symptoms-such as loss of or altered sense of smell; constipation; low blood pressure on rising to stand; sleep disturbances; and depression-are present in most cases of PD, often for years before any of the primary motor symptoms appear.

137. There is currently no cure for PD. No treatment will slow, stop, or reverse its progression, and the treatments most-commonly prescribed for its motor symptoms tend to become progressively less effective, and to cause unwelcome side effects, the longer they are used.

2. Pathophysiology

138. The selective degeneration and death of dopaminergic neurons (dopamine-producing nerve cells) in a part of the brain called the substantia nigra pars compacta (“SNpc”) is

one of the primary pathophysiological hallmarks of PD.

139. Dopamine is a neurotransmitter (a chemical messenger that transmits signals from one neuron to another neuron, muscle cell, or gland cell) that is critical to the brain's control of motor function (among other things).

140. The death of dopaminergic neurons in the SNpc decreases the production of dopamine.

141. Once dopaminergic neurons die, they are not replaced; when enough dopaminergic neurons have died, dopamine production falls below the level the brain requires for proper control of motor function, resulting in the motor symptoms of PD.

142. The presence of Lewy bodies (insoluble aggregates of a protein called alpha-synuclein) in many of the remaining dopaminergic neurons in the SNpc is another of the primary pathophysiological hallmarks of PD.

143. Dopaminergic neurons are particularly susceptible to oxidative stress, a disturbance in the normal balance between oxidants present in cells and cells' antioxidant defenses.

144. Scientists who study PD generally agree that oxidative stress is a major factor in—if not the precipitating cause of—the degeneration and death of dopaminergic neurons in the SNpc and the accumulation of Lewy bodies in the remaining dopaminergic neurons that are the primary pathophysiological hallmarks of PD.

F. Paraquat's toxicity

145. Paraquat is highly toxic to both plants and animals.

146. Paraquat injures and kills plants by creating oxidative stress that causes or contributes to cause the degeneration and death of plant cells.

147. Paraquat injures and kills humans and other animals by creating oxidative stress that causes or contributes to cause the degeneration and death of animal cells.

1 148. Paraquat creates oxidative stress in the cells of plants and animals because of “redox
2 properties” that are inherent in its chemical composition and structure: it is a strong oxidant, and
3 it readily undergoes “redox cycling” in the presence of molecular oxygen, which is plentiful in
4 living cells.

5 149. The redox cycling of paraquat in living cells interferes with cellular functions that
6 are necessary to sustain life—photosynthesis in the case of plant cells and cellular respiration in
7 the case of animal cells.

8 150. The redox cycling of paraquat in living cells creates a “reactive oxygen species”
9 known as superoxide radical, an extremely reactive molecule that can initiate a cascading series of
10 chemical reactions that creates other reactive oxygen species that damage lipids, proteins, and
11 nucleic acids—molecules that are essential components of the structures and functions of living
12 cells.

13 151. Because the redox cycling of paraquat can repeat indefinitely in the conditions
14 typically present in living cells, a single molecule of paraquat can trigger the production of
15 countless molecules of destructive superoxide radical.

16 152. Paraquat’s redox properties have been known since at least the 1930s.

17 153. That paraquat is toxic to the cells of plants and animals because it creates oxidative
18 stress through redox cycling has been known since at least the 1960s.

19 154. The surfactants with which the concentrates containing paraquat manufactured,
20 distributed, and sold by Defendants and Defendants’ corporate predecessors typically were
21 formulated were likely to increase paraquat’s toxicity to humans by increasing its ability to stay in
22 contact with or penetrate the skin, mucous membranes, and other epithelial tissues, including
23 tissues of the mouth, nose and nasal passages, trachea, and conducting airways, the lungs, and the
24
25

1 gastrointestinal tract.

2 **G. Paraquat and Parkinson's disease**

3 155. The same redox properties that make paraquat toxic to plant cells and other types
4 of animal cells make it toxic to dopaminergic neurons—paraquat is a strong oxidant that interferes
5 with the function of, damages, and ultimately kills dopaminergic neurons by creating oxidative
6 stress through redox cycling.

7 156. Although PD is not known to occur naturally in any species other than humans, PD
8 research is often performed using “animal models,” in which scientists artificially produce in
9 laboratory animals’ conditions that show features of PD.

10 157. Paraquat is one of only a handful of toxins that scientists use to produce animal
11 models of PD.

12 158. In animal models of PD, hundreds of studies involving various routes of exposure
13 have found that paraquat creates oxidative stress that results in the degeneration and death of
14 dopaminergic neurons in the SNpc, other pathophysiology consistent with that seen in human PD,
15 and motor deficits and behavioral changes consistent with those commonly seen in human PD.

16 159. Hundreds of in vitro studies have found that paraquat creates oxidative stress that
17 results in the degeneration and death of dopaminergic neurons (and many other types of animal
18 cells).

19 160. Many epidemiological studies (studies of the patterns and causes of disease in
20 defined populations) have found an association between paraquat exposure and PD, including
21 multiple studies finding a two- to five-fold or greater increase in the risk of PD in populations with
22 occupational exposure to paraquat compared to populations without such exposure.

23 161. Defendants had knowledge of these studies and the relationship between paraquat
24 exposure and PD but actively and fraudulently concealed this information from Plaintiff and
25 COMPLAINT AND DEMAND FOR JURY
Page 24

1 others.

2 **H. Paraquat regulation**

3 162. The Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), 7 U.S.C. §
4 136 et seq., which regulates the distribution, sale, and use of pesticides within the United States,
5 requires that pesticides be registered with the EPA prior to their distribution, sale, or use, except
6 as described by FIFRA. 7 U.S.C. 136a(a).

7 163. As part of the pesticide registration process, the EPA requires, among other things,
8 a variety of tests to evaluate the potential for exposure to pesticides, toxicity to people and other
9 potential non-target organisms, and other adverse effects on the environment.

10 164. As a general rule, FIFRA requires registrants to perform health and safety testing
11 of pesticides.

12 165. FIFRA does not require the EPA to perform health and safety testing of pesticides
13 itself, and the EPA generally does not perform such testing.

14 166. The EPA registers (or re-registers) a pesticide if it believes, based largely on studies
15 and data submitted by the registrant, that:

- 16
- 17 a. its composition is such as to warrant the proposed claims for it, 7 U.S.C. §
 - 18 136a(c)(5)(A);
 - 19 b. its labeling and other material required to be submitted comply with the
 - 20 requirements of FIFRA, 7 U.S.C. § 136a(c)(5)(B);
 - 21 c. it will perform its intended function without unreasonable adverse effects on the
 - 22 environment, 7 U.S.C. § 136a(c)(5)(C); and
 - 23 d. when used in accordance with widespread and commonly recognized practice it
 - 24 will not generally cause unreasonable adverse effects on the environment, 7 U.S.C. §
 - 25 136a(c)(5)(D).

1 167. FIFRA defines “unreasonable adverse effects on the environment” as “any
2 unreasonable risk to man or the environment, taking into account the economic, social, and
3 environmental costs and benefits of the use of any pesticide.” 7 U.S.C. § 136(bb).

4 168. Under FIFRA, “[a]s long as no cancellation proceedings are in effect registration
5 of a pesticide shall be prima facie evidence that the pesticide, its labeling and packaging comply
6 with the registration provisions of [FIFRA].” 7 U.S.C. § 136a(f)(2).

7 169. However, FIFRA further provides that “[i]n no event shall registration of an article
8 be construed as a defense for the commission of any offense under [FIFRA].” 7 U.S.C. §
9 136a(f)(2).

10 170. The distribution or sale of a pesticide that is misbranded is an offense under FIFRA,
11 which provides in relevant part that “it shall be unlawful for any person in any State to distribute
12 or sell to any person . . . any pesticide which is . . . misbranded.” 7 U.S.C. § 136j(a)(1)(E).

13 171. A pesticide is misbranded under FIFRA if, among other things:

14 a. its labeling bears any statement, design, or graphic representation relative thereto
15 or to its ingredients that is false or misleading in any particular, 7 U.S.C. §
16 136(q)(1)(A);

17 b. the labeling accompanying it does not contain directions for use which are
18 necessary for effecting the purpose for which the product is intended and if complied
19 with, together with any requirements imposed under Section 136a(d) of the title, are
20 adequate to protect health and the environment, 7 U.S.C. § 136(q)(1)(F); or

21 c. the label does not contain a warning or caution statement that may be necessary and
22 if complied with, together with any requirements imposed under section 136a(d) of the
23 title, is adequate to protect health and the environment,” 7 U.S.C. § 136(q)(1)(G).

24 172. Plaintiff does not seek in this action to impose on Defendants any labeling or
25

1 packaging requirement in addition to or different from those required under FIFRA; accordingly,
 2 any allegation in this complaint that a Defendant breached a duty to provide adequate directions
 3 for the use of paraquat or warnings about paraquat, breached a duty to provide adequate packaging
 4 for paraquat, or concealed, suppressed, or omitted to disclose any material fact about paraquat or
 5 engaged in any unfair or deceptive practice regarding paraquat, that allegation is intended and
 6 should be construed to be consistent with that alleged breach, concealment, suppression, or
 7 omission, or unfair or deceptive practice, having rendered the paraquat “misbranded” under
 8 FIFRA; however, Plaintiff brings claims and seek relief in this action only under state law, and do
 9 not bring any claims or seek any relief in this action under FIFRA.

11 V. ALLEGATIONS COMMON TO SPECIFIC CAUSES OF ACTION

12 A. Strict product liability – design defect

13 173. At all relevant times, Defendants and Defendants’ corporate predecessors were
 14 engaged in the U.S. paraquat business.

15 174. At all relevant times, Defendants and Defendants’ corporate predecessors were
 16 engaged in the business of designing, manufacturing, distributing, and selling pesticides, and
 17 designed, manufactured, distributed, and sold paraquat intending or expecting that it would be sold
 18 and used in Washington.

19 175. Plaintiff was exposed to paraquat sold and used in Washington that Defendants and
 20 Defendants’ corporate predecessors designed, manufactured, distributed, and sold intending or
 21 expecting that it would be sold and used in Washington.

22 176. The paraquat that Defendants and Defendants’ corporate predecessors designed,
 23 manufactured, distributed, and sold and to which Plaintiff was exposed was in a defective
 24 condition that made it unreasonably dangerous, in that when used in the intended and directed
 25 manner or a reasonably foreseeable manner:

1 a. it was designed, manufactured, formulated, and packaged such that it was likely to
2 be inhaled, ingested, and absorbed into the bodies of persons who used it, who were
3 nearby while it was being used, or who entered fields or orchards where it had been
4 sprayed or areas near where it had been sprayed; and

5 b. when inhaled, ingested, or absorbed into the bodies of persons who used it, who
6 were nearby while it was being used, or who entered fields or orchards where it had
7 been sprayed or areas near where it had been sprayed, it was likely to cause or
8 contribute to cause latent neurological damage that was both permanent and
9 cumulative, and repeated exposures were likely to cause or contribute to cause
10 clinically significant neurodegenerative disease, including PD, to develop long after
11 exposure.

12 177. This defective condition existed in the paraquat that Defendants and Defendants'
13 corporate predecessors designed, manufactured, distributed, and sold and to which Plaintiff was
14 exposed when it left the control of Defendants and Defendants' corporate predecessors and was
15 placed into the stream of commerce.

16 178. As a result of this defective condition, the paraquat that Defendants and
17 Defendants' corporate predecessors designed, manufactured, distributed, and sold and to which
18 Plaintiff was exposed either failed to perform in the manner reasonably to be expected in light of
19 its nature and intended function, or the magnitude of the dangers outweighed its utility.

20 179. The paraquat that Defendants and Defendants' corporate predecessors designed,
21 manufactured, distributed, and sold and to which Plaintiff was exposed was used in the intended
22 and directed manner or a reasonably foreseeable manner.

23 **B. Strict product liability – failure to warn**

24 180. At all times relevant to this claim, Defendants and Defendants' corporate
25

1 predecessors were engaged in the business of designing, manufacturing, distributing, and selling
2 pesticides, and designed, manufactured, distributed, and sold paraquat intending or expecting that
3 it would be sold and used in Washington.

4 181. Plaintiff was exposed to paraquat sold and used in Washington that Defendants and
5 Defendants' corporate predecessors designed, manufactured, distributed, and sold intending or
6 expecting that it would be sold and used in Washington.

7 182. When Defendants and Defendants' corporate predecessors designed,
8 manufactured, distributed, and sold the paraquat to which Plaintiff was exposed, Defendants and
9 Defendants' corporate predecessors knew or in the exercise of ordinary care should have known
10 that when used in the intended and directed manner or a reasonably foreseeable manner:
11

12 a. it was designed, manufactured, formulated, and packaged such that it was likely to
13 be inhaled, ingested, and absorbed into the bodies of persons who used it, who were
14 nearby while it was being used, or who entered fields or orchards where it had been
15 sprayed or areas near where it had been sprayed; and

16 b. when inhaled, ingested, or absorbed into the bodies of persons who used it, who
17 were nearby while it was being used, or who entered fields or orchards where it had
18 been sprayed or areas near where it had been sprayed, it was likely to cause or
19 contribute to cause latent neurological damage that was both permanent and
20 cumulative, and repeated exposures were likely to cause or contribute to cause
21 clinically significant neurodegenerative disease, including PD, to develop long after
22 exposure.

23 183. The paraquat that Defendants and Defendants' corporate predecessors designed,
24 manufactured, distributed, and sold and to which Plaintiff was exposed was in a defective
25 condition that made it unreasonably dangerous when it was used in the intended and directed

1 manner or a reasonably foreseeable manner, in that:

2 a. it was not accompanied by directions for use that would have made it unlikely to
3 be inhaled, ingested, and absorbed into the bodies of persons who used it, who were
4 nearby while it was being used, or who entered fields or orchards where it had been
5 sprayed or areas near where it had been sprayed; and

6 b. it was not accompanied by a warning that when inhaled, ingested, or absorbed into
7 the bodies of persons who used it, who were nearby while it was being used, or who
8 entered fields or orchards where it had been sprayed or areas near where it had been
9 sprayed, it was likely to cause or contribute to cause latent neurological damage that
10 was both permanent and cumulative, and that repeated exposures were likely to cause
11 or contribute to cause clinically significant neurodegenerative disease, including PD,
12 to develop long after exposure.

13 184. This defective condition existed in the paraquat that Defendants and Defendants'
14 corporate predecessors designed, manufactured, distributed, and sold and to which Plaintiff was
15 exposed when it left the control of Defendants and Defendants' corporate predecessors and was
16 placed into the stream of commerce.

17 185. As a result of this defective condition, the paraquat that Defendants and
18 Defendants' corporate predecessors designed, manufactured, distributed, and sold and to which
19 Plaintiff was exposed either failed to perform in the manner reasonably to be expected in light of
20 its nature and intended function, or the magnitude of the dangers outweighed its utility.

21 186. The paraquat that Defendants and Defendants' corporate predecessors designed,
22 manufactured, distributed, and sold and to which Plaintiff was exposed was used in the intended
23 and directed manner or a reasonably foreseeable manner.

24 **C. Negligence**

1 187. At all times relevant to this claim, Defendants and Defendants' corporate
2 predecessors were engaged in the business of designing, manufacturing, distributing, and selling
3 pesticides, and designed, manufactured, distributed, and sold paraquat intending or expecting that
4 it would be sold and used in Washington.

5 188. Plaintiff was exposed to paraquat sold and used in Washington that Defendants and
6 Defendants' corporate predecessors designed, manufactured, distributed, and sold intending or
7 expecting that it would be sold and used in Washington.

8 189. The paraquat that Defendants and Defendants' corporate predecessors designed,
9 manufactured, distributed, and sold and to which Plaintiff was exposed was used in the intended
10 and directed manner or a reasonably foreseeable manner.

11 190. At all times relevant to this claim, in designing, manufacturing, packaging, labeling,
12 distributing, and selling paraquat, Defendants and Defendants' corporate predecessors owed a duty
13 to exercise ordinary care for the health and safety of the persons whom it was reasonably
14 foreseeable could be exposed to it, including Plaintiff.

15 191. When Defendants and Defendants' corporate predecessors designed,
16 manufactured, packaged, labeled, distributed, and sold the paraquat to which Plaintiff was
17 exposed, it was reasonably foreseeable, and Defendants and Defendants' corporate predecessors
18 knew or in the exercise of ordinary case should have known, that when paraquat was used in the
19 intended and directed manner or a reasonably foreseeable manner:
20

21 a. it was designed, manufactured, formulated, and packaged such that it was likely to
22 be inhaled, ingested, and absorbed into the bodies of persons who used it, who were
23 nearby while it was being used, or who entered fields or orchards where it had been
24 sprayed or areas near where it had been sprayed; and

25 b. when inhaled, ingested, or absorbed into the bodies of persons who used it, who

1 were nearby while it was being used, or who entered fields or orchards where it had
 2 been sprayed or areas near where it had been sprayed, it was likely to cause or
 3 contribute to cause latent neurological damage that was both permanent and
 4 cumulative, and repeated exposures were likely to cause or contribute to cause
 5 clinically significant neurodegenerative disease, including PD, to develop long after
 6 exposure.

7 192. In breach of the aforementioned duty to Plaintiff, Defendants and Defendants'
 8 corporate predecessors negligently:

9 a. failed to design, manufacture, formulate, and package paraquat to make it unlikely
 10 to be inhaled, ingested, and absorbed into the bodies of persons who used it, who were
 11 nearby while it was being used, or who entered fields or orchards where it had been
 12 sprayed or areas near where it had been sprayed;

13 b. designed, manufactured, and formulated paraquat such that when inhaled, ingested,
 14 or absorbed into the bodies of persons who used it, who were nearby while it was being
 15 used, or who entered fields or orchards where it had been sprayed or areas near where
 16 it had been sprayed, it was likely to cause or contribute to cause latent neurological
 17 damage that was both permanent and cumulative, and repeated exposures were likely
 18 to cause or contribute to cause clinically significant neurodegenerative disease,
 19 including PD, to develop long after exposure;

20 c. failed to perform adequate testing to determine the extent to which exposure to
 21 paraquat was likely to occur through inhalation, ingestion, and absorption into the
 22 bodies of persons who used it, who were nearby while it was being used, or who entered
 23 fields or orchards where it had been sprayed or areas near where it had been sprayed;

24 d. failed to perform adequate testing to determine the extent to which paraquat spray
 25 drift was likely to occur, including its propensity to drift, the distance it was likely to

1 drift, and the extent to which paraquat spray droplets were likely to enter the bodies of
2 persons spraying it or other persons nearby during or after spraying;

3 e. failed to perform adequate testing to determine the extent to which paraquat, when
4 inhaled, ingested, or absorbed into the bodies of persons who used it, who were nearby
5 while it was being used, or who entered fields or orchards where it had been sprayed
6 or areas near where it had been sprayed, was likely to cause or contribute to cause latent
7 neurological damage that was both permanent and cumulative, and the extent to which
8 repeated exposures were likely to cause or contribute to cause clinically significant
9 neurodegenerative disease, including PD, to develop long after exposure;

10 f. failed to perform adequate testing to determine the extent to which paraquat, when
11 formulated or mixed with surfactants or other pesticides or used along with other
12 pesticides, and inhaled, ingested, or absorbed into the bodies of persons who used it,
13 who were nearby while it was being used, or who entered fields or orchards where it
14 had been sprayed or areas near where it had been sprayed, was likely to cause or
15 contribute to cause latent neurological damage that was both permanent and
16 cumulative, and the extent to which repeated exposures were likely to cause or
17 contribute to cause clinically significant neurodegenerative disease, including PD, to
18 develop long after exposure;

19 g. failed to direct that paraquat be used in a manner that would have made it unlikely
20 to have been inhaled, ingested, and absorbed into the bodies of persons who used it,
21 who were nearby while it was being used, or who entered fields or orchards where it
22 had been sprayed or areas near where it had been sprayed; and

23 h. failed to warn that when inhaled, ingested, or absorbed into the bodies of persons
24 who used it, who were nearby while it was being used, or who entered fields or orchards
25 where it had been sprayed or areas near where it had been sprayed, paraquat was likely

1 to cause or contribute to cause latent neurological damage that was both permanent and
 2 cumulative, and repeated exposures were likely to cause or contribute to cause
 3 clinically significant neurodegenerative disease, including PD, to develop long after
 4 exposure.

5 **D. Breach of implied warranty of merchantability**

6 193. At all times relevant to this claim, Defendants and Defendants' corporate
 7 predecessors were engaged in the business of designing, manufacturing, distributing, and selling
 8 paraquat and other restricted-use pesticides and themselves out as having knowledge or skill
 9 regarding paraquat and other restricted-use pesticides.

10 194. At all times relevant to this claim, Defendants and Defendants' corporate
 11 predecessors designed, manufactured, distributed, and sold paraquat intending or expecting that it
 12 would be sold and used in Washington.

13 195. Plaintiff was exposed to paraquat sold and used in Washington that Defendants and
 14 Defendants' corporate predecessors designed, manufactured, distributed, and sold intending or
 15 expecting that it would be sold and used in Washington.

16 196. At the time of each sale of paraquat to which Plaintiff was exposed, Defendants and
 17 Defendants' corporate predecessors impliedly warranted that it was of merchantable quality,
 18 including that it was fit for the ordinary purposes for which such goods were used.

19 197. Defendants and Defendants' corporate predecessors breached this warranty
 20 regarding each sale of paraquat to which Plaintiff was exposed, in that it was not of merchantable
 21 quality because it was not fit for the ordinary purposes for which such goods were used, and in
 22 particular:
 23

- 24 a. it was designed, manufactured, formulated, and packaged such that it was likely to
 25 be inhaled, ingested, and absorbed into the bodies of persons who used it, who were

1 nearby while it was being used, or who entered fields or orchards where it had been
 2 sprayed or areas near where it had been sprayed; and

3 b. when inhaled, ingested, or absorbed into the bodies of persons who used it, who
 4 were nearby while it was being used, or who entered fields or orchards where it had
 5 been sprayed or areas near where it had been sprayed, it was likely to cause or
 6 contribute to cause latent neurological damage that was both permanent and
 7 cumulative, and repeated exposures were likely to cause or contribute to cause
 8 clinically significant neurodegenerative disease, including PD, to develop long after
 9 exposure.

10 **COUNT 1**
 11 **DEFENDANTS SCPLLC AND SAG**
 12 **STRICT PRODUCT LIABILITY – DESIGN DEFECT**
PERSONAL INJURIES

13 198. Plaintiff incorporates by reference the foregoing paragraphs of this Complaint.

14 199. As a direct and proximate result of the defective and unreasonably dangerous
 15 condition of the paraquat manufactured, distributed, and sold by SCPLLC, SAG, and their
 16 corporate predecessors, Plaintiff developed PD; has suffered severe and permanent physical pain,
 17 mental anguish, and disability, and will continue to do so for the remainder of his life; has suffered
 18 the loss of a normal life and will continue to do so for the remainder of his life; has lost income
 19 that he otherwise would have earned and will continue to do so for the remainder of his life; and
 20 has incurred reasonable expenses for necessary medical treatment and will continue to do so for
 21 the remainder of his life.

22 **COUNT 2**
 23 **DEFENDANTS SCPLLC AND SAG**
 24 **STRICT PRODUCT LIABILITY – FAILURE TO WARN**
PERSONAL INJURIES

25 200. Plaintiff incorporates by reference the foregoing paragraphs of this Complaint.

1 201. As a direct and proximate result of the lack of adequate directions for the use of
2 and warnings about the dangers of the paraquat manufactured, distributed and sold by SCPLLC,
3 SAG, and their corporate predecessors, Plaintiff developed PD; has suffered severe and permanent
4 physical pain, mental anguish, and disability, and will continue to do so for the remainder of his
5 life; has suffered the loss of a normal life and will continue to do so for the remainder of his life;
6 has lost income that he otherwise would have earned and will continue to do so for the remainder
7 of his life; and has incurred reasonable expenses for necessary medical treatment and will continue
8 to do so for the remainder of his life.
9

10 **COUNT 3**
11 **DEFENDANTS SCPLLC AND SAG**
12 **NEGLIGENCE**
13 **PERSONAL INJURIES**

14 202. Plaintiff incorporates by reference the foregoing paragraphs of this Complaint.

15 203. As a direct and proximate result of the negligence of SCPLLC, SAG, and their
16 corporate predecessors, Plaintiff developed PD; has suffered severe and permanent physical pain,
17 mental anguish, and disability, and will continue to do so for the remainder of his life; has suffered
18 the loss of a normal life and will continue to do so for the remainder of his life; has lost income
19 that he otherwise would have earned and will continue to do so for the remainder of his life; and
20 has incurred reasonable expenses for necessary medical treatment and will continue to do so for
21 the remainder of his life.

22 **COUNT 4**
23 **DEFENDANTS SCPLLC AND SAG**
24 **BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY**
25 **PERSONAL INJURIES**

26 204. Plaintiff incorporates by reference the foregoing paragraphs of this Complaint.

27 205. As a direct and proximate result of the breaches of the implied warranty of

1 merchantability by SCPLLC, SAG, and their corporate predecessors, Plaintiff developed PD; has
2 suffered severe and permanent physical pain, mental anguish, and disability, and will continue to
3 do so for the remainder of his life; has suffered the loss of a normal life and will continue to do so
4 for the remainder of his life; has lost income that he otherwise would have earned and will continue
5 to do so for the remainder of his life; and has incurred reasonable expenses for necessary medical
6 treatment and will continue to do so for the remainder of his life.

7
8 **PRAYER FOR RELIEF**

9 206. As a result of the foregoing, Plaintiff respectfully requests that this Court enter
10 judgment in his favor and against Defendants, jointly and severally, for compensatory damages,
11 costs, pre- and post-judgment interest, and attorneys' fees, severally for punitive damages, and for
12 such further relief to which he may show himself to be entitled.

13 **DEMAND FOR JURY TRIAL**

14 207. Pursuant to FED. R. CIV. P. 38(b), Plaintiff respectfully demands a jury trial on all
15 issues triable by jury.

16 Dated: December 29, 2021

17
18 Respectfully submitted,

19 **PHILLIPS LAW FIRM, PLLC**

20 */s/ Doug Weinmaster*

21 Doug Weinmaster

22 17410 133rd Ave. N.E., Suite #301

23 Woodinville, Washington 98072-3200

24 Tel.: 425-482-1111

25 Email: DWeinmaster@justiceforyou.com

**MILBERG COLEMAN BRYSON
PHILLIPS GROSSMAN, PLLC**

/s/ Randi Kassan

Randi Kassan*

Milberg Coleman Bryson Phillips Grossman, PLLC

100 Garden City Plaza, Suite 500

Garden City, New York 11530

Tel.: 212-594-5300

Email: rkassan@milber.com

Phone: (516) 741-5600

Fax: (516) 741-0128

**Pro Hac Vice Forthcoming*

*Attorneys for Plaintiff and the Proposed
Class*